Actively Recruiting
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Led by Shanghai Pulmonary Hospital, Shanghai, China · Updated on 2026-04-13
690
Participants Needed
14
Research Sites
482 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the non-inferiority in recurrence-free survival and overall survival of segmentectomy compared with lobectomy in patients with lung adenocarcinoma ≤ 2 cm with micropapillary and solid subtype negative by intraoperative frozen sections.
CONDITIONS
Official Title
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient aged 20-79 years old, both male or female
- Tumor size \u2264 2cm on preoperative CT scan
- Peripheral solitary nodule or associated lesion is minimally invasive adenocarcinoma (MIA) or less invasive lesion
- Preoperative CT shows nodules are non-pure ground glass nodules (consolidation to tumor ratio \u2265 0.25)
- Intraoperative frozen section confirms invasive lung adenocarcinoma with micropapillary and solid subtype negative (\u2264 5%)
- Intraoperative frozen section shows resection margins free of tumor cells
- Lung function can tolerate both segmentectomy and lobectomy (FEV1 > 1.5L or FEV1% \u2265 60%)
- Eastern Cooperative Oncology Group performance status 0 to 2
- Voluntary participation with signed informed consent and ability to comply with follow-up and study requirements
You will not qualify if you...
- Radiological pure ground glass nodules (consolidation to tumor ratio < 0.25)
- Nodule is close to lung hilus preventing segmentectomy
- Intraoperative frozen section shows micropapillary and solid subtype positive (> 5%)
- Intraoperative frozen section confirms adenocarcinoma in situ or minimally invasive adenocarcinoma
- Preoperative imaging or EBUS indicates lymph node positive metastasis
- Preoperative imaging shows distant metastasis
- Severe heart, liver, or kidney damage (grade 3-4, ALT/AST over 3 times normal, creatinine over normal)
- Other malignant tumors
- Pregnant, planning pregnancy, or lactating females (urine HCG > 2500 IU/L indicating early pregnancy)
- Prior chemotherapy, radiation, or other therapy; participation in other tumor clinical trials within 3 months
- Investigator assessment determines unsuitability for trial participation
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 14 locations
1
Anhui Chest Hospital
Hefei, Anhui, China
Actively Recruiting
2
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China
Actively Recruiting
3
Nanyang Central Hospital
Nanyang, Henan, China
Actively Recruiting
4
The Sixth People's Hospital of Nantong
Nantong, Jiangsu, China, 216002
Actively Recruiting
5
Affiliated Hospital of Nantong University
Nantong, Jiangsu, China, 226001
Actively Recruiting
6
Affiliated Hospital of Xuzhou Medical University
Xuzhou, Jiangsu, China
Actively Recruiting
7
Yancheng First People's Hospital
Yancheng, Jiangsu, China
Actively Recruiting
8
Shandong Public Health Clinical Center
Jinan, Shandong, China
Actively Recruiting
9
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, China, 200433
Actively Recruiting
10
Huadong Hospital
Shanghai, Shanghai Municipality, China
Actively Recruiting
11
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, China, 310009
Actively Recruiting
12
Huzhou Central Hospital
Huzhou, Zhejiang, China
Actively Recruiting
13
Ningbo First Hospital
Ningbo, Zhejiang, China
Actively Recruiting
14
Ningbo No.2 Hospital
Ningbo, Zhejiang, China
Actively Recruiting
Research Team
H
Hang Su
CONTACT
C
Chang Chen, MD, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here